Thiotetrabarbital is a thiobarbituric acid derivative patented by "Centre national de la recherche scientifique" as a short-acting anesthetic agent useful in veterinary medicine.

Crufomate is an insecticide and antihelmintic drug which acts by inhibition of acetylcholinesterase. Crufomate was used on or in cattle, sheep, and goats to control internal cattle grubs and external horn flies and cattle lice. Crufomate is administered by injection, oral administration, and spraying. For the treatment of internal helminth parasites, crufomate is administered by the oral drench directly into the rumen.

Picafibrate is clofibrate derivative. It is a hypocholesteraemic agent. Fibrates reduce plasma triglycerides by inhibiting their hepatic synthesis and increasing their catabolism. These effects are due to activation of peroxisome proliferator-activated receptors (PPAR alpha) and induction of the over-expression of genes containing a peroxisome proliferator response element (PPRE) in their promoter.

Ethyl dirazepate is an anticonvulsant compound.

Nisbuterol, a nicotinic acid ester, is a bronchodilator.

Nolomirole (CHF1035) is an orally active, selective dopamine agonist, primarily activating DA2- and alpha2 receptors, thereby inhibiting norepinephrine release, which may be beneficial in heart failure. Nolomirole is able to attenuate the heart failure signs in the monocrotaline-induced congestive heart failure. CHF1035 is a mixture of two enantiomers, CHF1800 (+) and CHF1810 (-). CHF1035 and its metabolite CHF1024 significantly decreased the IOP in rabbits, and are potential novel IOP lowering agents. Especially, CHF1035 produced a substantial decrease in IOP for a prolonged period of time, and thus may prove useful in glaucoma therapy. Nolomirole is a pre-synaptic stimulator of DA2-dopaminergic and α2-adrenergic receptors in peripheral sympathetic nerve endings. These receptors act as a negative feedback mechanism, inhibiting norepinephrine secretion. In early phase clinical studies lasting 1–3 months, nolomirole reduced peripheral systemic resistance and 24 hour blood pressure and increased cardiac output. In a study of 29 patients with heart failure, followed for 10 days, a reduction in plasma norepinephrine was demonstrated. In spite of the fact that Nolomirole was in clinical trials for the treatment of heart failure, its development was discontinued.

Proadifen is an inhibitor of drug metabolism and cytochrome P450 enzyme system activity. It stimulated the release of prostacyclin (PGI2) from the rabbit aorta, bovine aorta and human umbilical vein in vitro, but had no effect on cultured smooth muscle from the bovine aortic media. In human platelets, proadifen inhibited prostaglandin and thromboxane production induced by A23187, thrombin, and ADP. Proadifen might thus constitute the prototype of a new class of antiplatelet drugs.

Auriclosene (previously known as NVC-422) is a broad-spectrum, fast-acting topical anti-infective agent against microbial pathogens, including antibiotic-resistant microbes. It has been investigated in phase II clinical trials for the treatment of bacterial conjunctivitis and as a topical gel in children with impetigo. In addition, using a guinea pig model was shown, that auriclosene was effective in the treatment of dermatophytosis, including onychomycosis.

Hydroxytoluic acid is a long-acting derivative of salicylate with antilipidemic properties. It shows fibrinolytic activity in human plasma by activating the fibrinolytic system and has been shown to lower plasma free fatty acid, cholesterol levels, and to raise metabolic oxygen consumption.